title: Widespread renal polycystosis induced by crizotinib.
abstract: With the widespread availability of biological antitumor drugs, the current scene of chemotherapies is changing. New chemotherapy agents, such as crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK) and ROS1, usually used in pretreated advanced ALK-positive non-small-cell lung carcinoma, are more often used, and a description of the onset of side effects with suggestions for their management could be of interest for physicians. We describe a case of diffuse and aggressive renal polycystosis induced by crizotinib, which regressed after therapy, which could be of interest considering its wide extension and disappearance after the end of treatment. We also suggest some considerations from the literature and from the case reported that could be helpful in the management of this condition, which is known to be caused by crizotinib treatment.
authors.affiliation: Department of Radiology, Sapienza University of Rome, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Rome - Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Di Girolamo
authors.forename: Ida
authors.initials: I
authors.lastname: Paris
authors.forename: Francesco
authors.initials: F
authors.lastname: Carbonetti
authors.forename: Elisa Concetta
authors.initials: EC
authors.lastname: Onesti
authors.forename: Fabio
authors.initials: F
authors.lastname: Socciarelli
authors.forename: Paolo
authors.initials: P
authors.lastname: Marchetti
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001707:Biopsy, Needle; D001859:Bone Neoplasms / Q000556:secondary; D001932:Brain Neoplasms / Q000532:radiotherapy / Q000556:secondary; D003287:Contrast Media; D000077547:Crizotinib; D003560:Cysts / Q000139:chemically induced*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008854:Microscopy, Electron; D058990:Molecular Targeted Therapy / Q000379:methods; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D014057:Tomography, X-Ray Computed / Q000379:methods; D014178:Translocation, Genetic
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases